Introduction
============

Medication adherence is an under-addressed area in health care, with approximately 50% of patients with a chronic illness not taking their prescribed regimens as directed.[@b1-iprp-6-131],[@b2-iprp-6-131] As advancements in pharmacotherapeutics mean little if patients do not adhere to their prescribed regimen, increasing medication adherence through a combination of patient and physician-based interventions will likely have a significant effect on medical outcomes.[@b3-iprp-6-131],[@b4-iprp-6-131] Poor medication adherence to smoking cessation aids has been a long-standing problem in combating tobacco use, including for the most effective smoking cessation aid Champix^®^ (\[1.0 mg varenicline tartrate\] Pfizer, Inc., New York, NY, USA), which requires at least 3 months of therapy to effectively support a quit attempt.[@b5-iprp-6-131] Research into varenicline adherence has found a correlation between prolonged smoking abstinence and adherence to the prescribed varenicline regimen.[@b6-iprp-6-131],[@b7-iprp-6-131]

Dose administration aids (DAAs) are one potential avenue to increase medication adherence, as they can simplify complex regimens by repackaging medications into easily-followed compartmentalized devices.[@b8-iprp-6-131],[@b9-iprp-6-131] The elderly, those with mental illnesses, and those on multiple medications may benefit from the increased convenience and reduced error associated with DAA use. However, there are some issues associated with DAAs, primarily that some medications cannot be physically stored together due to surface interactions, and the risk of compromised physical and/or chemical stability.[@b10-iprp-6-131] Exposure to heat, humidity, oxygen, and light can all contribute to physical degradation of the dosage form and/or chemical degradation of the active pharmaceutical ingredient or excipients in the medication. Medication stability guarantees by manufacturers are also invalidated upon removal from the original packaging, meaning an informed decision is required to be made by health professionals prior to committing to repackaging medications into a DAA.[@b8-iprp-6-131]-[@b11-iprp-6-131]

Webster-pak^®^ is a commonly utilized DAA device in community pharmacies in Australia, though they are often used without the availability of published data on the stability of individually repackaged medications. Commonly used and repackaged medications such as aspirin, atenolol, furosemide, and sodium valproate have all been reported to demonstrate physical or chemical instability upon repackaging.[@b12-iprp-6-131]-[@b17-iprp-6-131] The objective of this research was thus to determine the physical and chemical stability of varenicline tartrate, when repackaged into a DAA and stored under ambient temperature and humidity conditions in order to recommend its suitability for repackaging in clinical practice.

Methods
=======

Conditions
----------

To determine whether commercial varenicline tartrate tablets are suitable for repackaging, tests were performed to identify any issues in relation to physical or chemical stability between the repackaged and control tablets. Varenicline tablets were purchased from a local pharmacy, removed from their original packaging, and repackaged individually into Multi Dose Webster-pak blister compartments. Gloves and plastic packing tweezers were used to handle tablets, and all tablets had a remaining shelf-life of at least 9 months at the time of sampling.

The DAAs were stored at ambient conditions (30 ± 2°C and 75 ± 5% relative humidity) for a period of 42 days in a KBF 720 Climate Chamber (Binder GmbH, Tuttlingen, Germany). Control tablets were removed from their original packaging immediately prior to analysis. A duration of 42 days was chosen as the results of this study are required prior to conducting a randomized controlled trial in which participants are to be given varenicline tartrate tablets repackaged in Webster-pak blister compartments. This duration complies with the Pharmaceutical Society of Australia guidelines which recommend a maximum repackaged duration of 8 weeks.[@b18-iprp-6-131]

Physical stability testing
--------------------------

Weight uniformity, physical appearance, thickness, hardness, friability, dissolution and disintegration rates were all evaluated according to the British Pharmacopeia compendial requirements. Weight uniformity was tested by individually weighing 20 tablets on an AND HM-200 analytical balance. Thickness and hardness of ten tablets were measured using a Vankel VK200 instrument, the disintegration of six tablets was assessed using a Varian VK100 disintegration apparatus, and friability testing of 20 tablets was performed using a Vankel Friabilator.[@b19-iprp-6-131]

Dissolution was measured for six tablets using a Vankel VK7000 dissolution apparatus with a 100 mL vessel by placing a 1.0 mg varenicline tartrate tablet in 100 mL of reverse osmosis water (pH 5.2) at 37 ± 0.5°C. The rotating paddle was set to 100 r/min, and samples withdrawn at 0 and 45 minutes. Samples were assessed for drug content using high performance liquid chromatography (HPLC) (see following section). The dissolution results were analyzed using a two-tailed Mann-Whitney *U* test (*p* = 0.05), performed with IBM SPSS Statistics Version 23 (IBM Corp., Armonk, NY, USA).

Chemical stability testing
--------------------------

Varenicline tartrate content was measured using an HPLC method validated for specificity, linearity, accuracy, and precision as per the International Council on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) guideline Q2/R1.[@b20-iprp-6-131] A Nexera-i LC-2040C 3D liquid chromatograph was used to perform content analysis on samples, using a mobile phase composed of 12% acetonitrile, 88% water, and 0.1% formic acid. An XSelect HSS T3 5 µm (4.6 mm × 250 mm) column was used with a flow rate of 1 mL/min, heated to 40°C. The detection wavelength was set at 237 nm, and the injection volume at 10 µL.

Photostability testing involved placing 20 tablets in a Webster-pak within a Heraeus Suntest CPS+ with a Solar ID65 filter and irradiating at 500 watt/m^2^ for 10.6 hours, equating to 1.2 million lux hours of exposure to visible light, and 496 WH/m^2^ of ultraviolet light. This is in accordance with minimum exposure requirements in ICH guideline Q1B.[@b21-iprp-6-131] A control of 20 tablets (wrapped in aluminum foil) was used to determine the effect of temperature. Content analysis was conducted on control samples, covered and exposed photosta-bility samples, and samples from the tablets stored at ambient conditions. Samples were prepared by crushing 20 tablets in a mortar and pestle, weighing out an amount of powder equivalent to one varenicline tartrate tablet, and dissolving in water. Samples were filtered through a Millex-GP 0.22 µm polyethersulfone-membrane express filter and analyzed by HPLC using a calibration curve in the range of 0 to 20 µg/L.

Results
=======

Physical stability
------------------

Tablet appearance did not change after storage under ambient conditions, or after exposure to visible and ultraviolet light, with each tablet retaining their blue hue and oblong shape. A minor increase in tablet weight and thickness occurred after storage at ambient temperature and humidity, with the average tablet weight increasing by 1%, and average tablet thickness increasing by 4%. Significant changes in tablet hardness occurred, with the mean pressure to break the control tablets being 151 N, which decreased by 27% after storage at ambient conditions, to an average of 110 N. These changes led to brief adhesion to the sides of blister cells, though tablets dislodged quickly when moving the DAA, and did not cause any visual residue on the sides of the blister cells.

Disintegration times were also reduced, with control tablets disintegrating in 79 seconds, compared to 66 seconds for the ambient tablets, a reduction of 16%. [Figure 1](#f1-iprp-6-131){ref-type="fig"} illustrates the changes in hardness and disintegration times and the relationship between these two physical characteristics. Fri-ability testing resulted in a small amount of weight gain per tablet in both groups, with tablets in the control group gaining an average of 85 µg, compared to 260 µg in the ambient group. Tablet dissolution was unaffected by the repackaging process, with samples taken after 45 minutes averaging 92% of drug content dissolved for the control tablets, and 93% for the tablets stored at ambient conditions (*p* = 0.887).

Chemical stability
------------------

Content analysis results of the covered tablets and the tablets exposed to light, and control tablets and those stored at ambient conditions (30°C/75% relative humidity) were all within the requirements of the compendial standard. There was no significant difference in varenicline tartrate content between the four groups. [Table 1](#t1-iprp-6-131){ref-type="table"} displays the content averages and 95% confidence intervals for the samples taken from the tablets within each group.

Discussion
==========

Ensuring the physical and chemical stability of medications is essential when attempting to reduce patient error and improve medication adherence by repackaging into a DAA such as a Webster-pak.[@b8-iprp-6-131]-[@b12-iprp-6-131] Varenicline tartrate content was not affected by repackaging and storage for 6 weeks at the worst temperature and humidity conditions for long-term stability testing recognized by the WHO.[@b22-iprp-6-131] Though the 0.5 mg var-enicline tablets were not tested, it is not believed their results would differ from the 1.0 mg tablets, as the only excipient difference is the coloring agent, and their duration of use in varenicline therapy is only 7 days at the beginning of therapy, minimizing their duration in the DAA.

Tablet hardness and disintegration times, although significantly affected, did not result in compromised physical stability of the dosage form or chemical stability of the drug. Commercially available varenicline tartrate tablets are pack aged in small, individual compartments with an aluminum backing within a cardboard sleeve, allowing significant protection from light, oxygen, and moisture. The Consumer Medicine Information leaflet also recommends storing the tablets in a cool, dry place below 30°C, specifically mentioning not to store them in the bathroom, near a sink, in the car, or on a window sill, and not to remove tablets from their packaging until a dose is needed.[@b23-iprp-6-131],[@b24-iprp-6-131]

A retrospective study of a cohort of 1,477 patients in a community-based setting found that zero and partial (\<80%) adherence had similar cessation rates (31.2% and 27.8%) respectively, whereas those who exhibited full adherence attained cessation rates of 50.7%.[@b6-iprp-6-131] A similar result was seen in the COMPASS Smoking Cessation Intervention Trial, with good adherence (\>80%) being associated with a 52% cessation rate at 6 months, compared to poor adherence, which resulted in a 25% cessation rate.[@b7-iprp-6-131] Poor adherence (and premature medication discontinuation) is often attributed to adverse effects, as well as smokers either having a perceived lack of efficacy or need for the medication.[@b5-iprp-6-131],[@b25-iprp-6-131]

While Webster-pak blister compartments assist in adherence when using multiple medications through the repackaging of tablets into individual compartments protected by an aluminum backing, the lack of a cardboard sleeve and the presence of a larger internal area for oxygen and moisture result in an increased exposure to light, oxygen, and moisture. An issue not addressed in this study is the potential for surface interactions between multiple medications packaged within the same blister compartment. Whilst individual var-enicline tartrate tablets can be safely repackaged into their own Webster-pak blister compartments, further research is required to assess this effect in other forms of DAAs. There is also the need to assess the likelihood of surface interactions and subsequent degradation of either varenicline or other medications in contact with each other.

Conclusion
==========

The DAA utilized in this study is one of the most commonly used in Australia, with pharmacists often seeking evidence-based recommendations on safe repackaging practices, as manufacturer assurances on stability are invalidated through repackaging. This is needed for both long-term and short-term medications, and those with unusual loading or unloading periods, such as varenicline tartrate. This study shows that 1.0 mg varenicline tartrate tablets repackaged in a Webster-pak will remain stable for a reasonable in-use period of 6 weeks when stored appropriately in tropical climates.
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![Variation in 1.0 mg varenicline tartrate tablet disintegration times (bars) and hardness (dotted line) between control tablets, and tablets stored at ambient conditions for 6 weeks.\
**Note:** Error bars represent 95% confidence intervals about the mean for n = 10 samples.](iprp-6-131Fig1){#f1-iprp-6-131}

###### 

Content with 95% confidence intervals (CIs) for 1.0 mg varenicline tartrate control tablets compared with those exposed to ambient temperature and humidity, and those exposed to light

  Storage conditions      Photostability conditions                            
  ----------------------- --------------------------- ------------------------ ------------------------
  99.3 (CI 97.4--101.2)   100.5 (CI 96.8--104.2)      100.9 (CI 95.6--106.2)   100.4 (CI 99.0--101.8)

**Notes:**

= 30 ± 2°C and 75 ± 5% relative humidity for 42 days;

= 1.2 million lux hours visible light and 496 WH/m^2^ ultraviolet light.
